<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450930</url>
  </required_header>
  <id_info>
    <org_study_id>PHYSCA-1</org_study_id>
    <secondary_id>2011-002687-25</secondary_id>
    <nct_id>NCT01450930</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency</brief_title>
  <acronym>PHYSCA</acronym>
  <official_title>Pharmacokinetics of Hydrocortisone After Subcutaneous Administration Compared With Intramuscular Injection in Chronic Adrenal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bruno Allolio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wuerzburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic adrenal insufficiency need to adapt their hydrocortisone replacement
      dose in conditions of physical or psychological stress to prevent life threatening adrenal
      crisis. In cases of more severe impairment or unsecure gastrointestinal absorption (e.g.
      gastroenteritis, severe infectious disease), parenteral administration of the hydrocortisone
      dose is crucial. The study is conducted to offer patients the possibility to perform
      hydrocortisone self administration in emergency situations in a way of administration which
      is easy to perform and accepted by the patient. Therefore, pharmacokinetics and safety of
      subcutaneous hydrocortisone administration will be studied and compared to intramuscular
      administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence Study</measure>
    <time_frame>4 hours</time_frame>
    <description>pharmakokinetic data (Cmax, time to Cmax, area under the curve of serum/salivary cortisol levels)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>3 days</time_frame>
    <description>number of adverse events after subcutaneous administration of hydrocortisone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Primary Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone subcutaneously first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocortisone subcutaneously first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrocortisone intramuscular first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocortisone intramuscular first</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone intramuscular first</intervention_name>
    <description>Hydrocortisone intramuscular first</description>
    <arm_group_label>Hydrocortisone intramuscular first</arm_group_label>
    <other_name>100 mg hydrocortisone (Pfizer®) in 2 ml solvent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone subcutaneously first</intervention_name>
    <description>Hydrocortisone subcutaneously first</description>
    <arm_group_label>Hydrocortisone subcutaneously first</arm_group_label>
    <other_name>100 mg hydrocortisone (Pfizer®) in 2 ml solvent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary adrenal insufficiency under standard glucocorticoid replacement therapy due to
             autoimmune adrenalitis or bilateral adrenalectomy (disease duration at least 12
             months),

          -  age ≥ 18 years,

          -  Patient´s written informed consent,

          -  Ability to comply with the protocol procedures

        Exclusion criteria

          -  Diabetes mellitus,

          -  Infectious disease with fever at time of investigation,

          -  Known intolerance to the study drug or constituents oft he study drug,

          -  Oral contraception,

          -  Known pregnancy or breast feeding,

          -  Renal failure (creatinine &gt; 2.5 ULN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefanie Hahner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Wuerzburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Medicine I, Endocrinology and Diabetology, University Hospital Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Wuerzburg</investigator_affiliation>
    <investigator_full_name>Bruno Allolio</investigator_full_name>
    <investigator_title>MD, Professor of Medicine, head of the Dept. of Endocrinology and Diabetology, University of Wuerzburg</investigator_title>
  </responsible_party>
  <keyword>Adrenal insufficiency</keyword>
  <keyword>Addison's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Addison Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

